References
- Allolio B., Hahner S., Weismann D., Fassnacht M. Management of adrenocortical carcinoma. Clin Endocrinol, 2004, 60: 273–287.
- Icard P., Goudet P., Charpenay C., Andreassian B., Carnaille B., Chapuis Y., Cougard P., Henry J. F., Proye C. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg, 2001, 25: 891–897.
- Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., Yazaki Y., Goto K., Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature, 332: 411–415.
- Donckier J., Hanet C., Berbinschi A., Galanti L., Robert A., Van Mechelen H., Pouleur H., Ketelslegers J. M. Cardiovascular and endocrine effects of endothelin-1 at patho-physiological and pharmacological concentrations in conscious dogs. Circulation, 1991, 84: 2476–2484.
- Grant K., Loisidou M., Taylor I. Endothelin-1: a multifunctional molecule in cancer. Br J Cancer, 2003, 88: 163–166.
- Nelson J., Bagnato A., Battistini B., Nisen P. The endothelin axis: emerging role in cancer. Nature, 2003, 3: 110–116.
- Nelson J. B., Chan-Tack K., Hedican S. P., Magnuson S. R., Opgenorth T. J., Bova G. S., Simons J. W. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res, 1996, 56: 663–668.
- Ahmed S. I., Thompson J., Coulson J. M., Woll P. J. Studies on the expression of endothelin, its receptor subtypes and converting enzymes in lung cancer and in human bronchial epithelium. Am J Respir Cell Mol Biol, 2000, 22: 422–431.
- Asham E., Shankae A., Loizidou M., Fredericks S., Miller K., Boulos P. B., Burnstock G., Taylor I. Increased endothelin-1 in colorectal cancer and reduction of tumor growth by ETA receptor antagonist. Br J Cancer, 2001, 85: 1759–1763.
- Wülfing P., Kersting C., Tio J., Fischer R. J., Wülfing C., Poremba C., Diallo R., Bocker W., Kiesel L. Endothelin-1, endothelin-ॅ-, and endothelin-B-receptor expression is correlated with vascular endothelial growth factor expression and angiogen-esis in breast cancer. Clin. Cancer Res, 2004, 10: 2393–2400.
- Thevarajah S., Udan M. S., Zheng H., Peluyg B. R., Nelson J. B. Endothelin axis expression in renal cell carcinoma. J Urol, 1999, 161: 137.
- Donckier J. E., Michel L., Van Beneden R., Delos M., Havaux X. Increased expression of endothelin-1 and its mitogenic receptor ETA in human papillary thyroid carcinoma. Clin Endocrinol, 2003, 59: 354–360.
- Carducci M. A., Padley R. J., Breul J., Vogelzang N. J., Zonnenberg B. A., Daliani D. D., Schulman C. C., Nabulsi A. A., Humerickhouse R. A., Weinberg M. A., Schmitt J. L., Nelson J. B. Effect of endothelin-ॅ receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized phase ii, placebo-controlled trial. J Clin Oncol, 2003, 21: 679–689.
- Saeger W. Histopathological classification of adrenal tumours. Eur J Clin Invest, 2000, 30: 58–62.
- Peduto Eberl L., Bovey R., Juillerat-Jeannerey L. Endothelin-receptor antagonists are proapoptotic and antiproliferative in human colon cancer cells. Br J Cancer, 2003, 88: 788–797.